Pharmaceutical regulatory affairs have undergone immense evolution over the past few years, thanks to significant advancements in technology and processes. The introduction of Electronic Common Technical Document (e-CTD) formats and digital dossier management systems have transformed the submission and approval processes for new drugs around the world.
The traditional regulatory systems rely on paper-based submissions, which require extensive costs, resources, and time to prepare documentation and get drug approvals. This is where employing e-CTD and digital dossier management systems come in, which not only supports faster submission processes but also improves the accuracy and reliability of the data presented to regulators.
In this article, we will give you a deeper insight into e-CTD and digital dossier management, their benefits, and how they can be implemented in traditional pharmaceutical regulatory affairs setups.
So without further ado, let’s dive in.
Understanding e-CTD and Digital Dossier Management
What is e-CTD?
Electronic Technical Document or e-CTD format is the digital version of the standard format used for submitting applications, amendments, supplements, and reports to the FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).
The USFDA has also published detailed guidance on compiling e-CTD submissions for pharmaceutical products.
Components of an e-CTD
The e-CTD is divided into several modules, each of which serves a distinct purpose. When preparing regulatory submissions, the regulatory affairs professionals follow the format of e-CTD in chronological order.
The main components of an e-CTD are:
● Module 1- Administrative Information: Module 1 makes up the first component of an e-CTD format. It contains region-specific administrative information and varies by country or region, reflecting the specific requirements of each regulatory body. Module 1 includes documentation like cover letter, application forms, table of contents, labeling information, and compliance certifications.
● Module 2: Common Technical Document Summaries: The second module of an e-CTD consists of summaries of the information that are later provided in Modules 3, 4, and 5. These summaries include Quality Overall Summary, Non-Clinical Overview, and Clinical Summary.
● Module 3 - Quality Information: As the name indicates, this module provides quality-related information on the drug substance and drug product. It compiles the quality information in two stages of the drug - as a drug substance that includes API and as a drug product that includes the drug in its final formulation. Stability data is also covered under this module.
● Module 4 - Non-Clinical Study Reports: Module 4 makes up the fourth component of e-CTD, providing detailed information on pre-clinical data. It consists of sections like pharmacology studies and toxicology studies.
● Module 5 -Clinical Study Reports: This is the last component of an e-CTD and it provides insight into the clinical trial data of the drug.
Benefits of Digital Dossier Management
While e-CTD serves as the perfect, paperless, and hassle-free alternative to traditional methods of compiling regulatory submissions, it still doesn’t simplify the cumbersome dossier management process. This is where digital dossier management comes in.
Digital dossier management systems are centralized repositories for all regulatory documents and data, allowing regulatory affairs professionals to store, access, and manage information from a single location, thus simplifying the retrieval process. It also reduces the risk of document loss and ensures that all stakeholders have access to the most current information at their fingertips.
Other benefits of digital dossier management are:
● It allows access to submission documents in real-time, making updates and revisions easier.
● Unlike paper-based systems, where the risk of errors is high, digital systems help ensure document integrity by implementing vers...
(All Rights Reserved)